admin – Page 4153 – Get News Story

Clinical Communication & Collaboration Market Top Companies Analysis, Industry Size, Share, Demand, Growth, In-Depth Insight, Business Opportunities And Forecast 2029

“Clinical Communication & Collaboration Market by Platform (Collaboration), Component (Badge, Nurse Call VOIP, Telehealth), Deployment, Application (Nurse Communication), End User (Hospital, ASC), Business Model, & Region – Global Forecast to 2029”

The size of global clinical communication and collaboration market in terms of revenue was estimated to be worth $2.6 billion in 2024 and is poised to reach $4.8 billion by 2029, growing at a CAGR of 13.2% from 2024 to 2029.

The global clinical communication and collaboration market, valued at US$2.4 billion in 2023, is forecasted to grow at a robust CAGR of 13.2%, reaching US$2.6 billion in 2024 and an impressive US$4.8 billion by 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics. Growth of the market is mainly driven by advantages of clinical communication solutions in enhancing patient care and safety, significant demand for cost-containment solutions within healthcare delivery systems, rising geriatric population, along with the growing adoption and prominence of big data and mHealth tools.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=118830286

Browse in-depth TOC on “Clinical Communication & Collaboration Market”

240 – Tables

50 – Figures

320 – Pages

Software segment accounted for the largest share of the global Clinical Communication and Collaboration market

On the basis component, the Clinical Communication and Collaboration market is segmented into hardware, software and services segment. The software segment accounted for the largest share of the component segment in 2023. The software segment comprises of clinical alerting & notification, physician & nurse scheduling systems, telehealth platform, collaborative care platforms. The clinical alerting & notification segment held the largest market share in the software segment. These systems plays a pivotal role in enhancing patient safety, as it reduces response times, and improves clinical decision-making. Moreover, the increasing focus on care coordination and continuity across healthcare settings has propelled the demand for robust clinical alerting and notification solutions. Owing to the many benefits of the software solutions, several healthcare providers are increasingly adopting these solutions for smooth workflows and enhanced quality care.

By application, physician communication segment accounted for the largest market share

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication. The physician communication segment held the largest market in 2023 due to its pivotal role in facilitating effective care delivery, and enhancing care coordination. Moreover, the unique communication needs of physicians, including the requirement for secure and confidential communication channels, further highlights the importance of dedicated physician communication solutions within the clinical communication and collaboration market. These solutions offer encrypted messaging, secure voice and video calling, and other advanced features tailored to the specific requirements of healthcare providers, enabling them to communicate effectively while adhering to stringent privacy and security regulations.

Hospitals & clinics are largest end users of the Clinical Communication and Collaboration market

Based on end users, the Clinical Communication and Collaboration market is segmented into hospitals & clinics, ambulatory surgical centers, long-term care facilities, nursing centers and other end-users which includes maternity care centers & fertility centers, and trauma and emergency care centers. The hospitals & clinics held the largest share among the end-users in 2023. From emergency departments and operating rooms to inpatient units and outpatient clinics, healthcare providers in hospitals and clinics rely heavily on effective communication channels to coordinate care plans, consult with colleagues, and ensure continuity of care for patients. As healthcare organizations continue to prioritize communication solutions that enhances care coordination, streamlines workflows, and support remote care delivery, hospitals and clinics are poised to remain key drivers of innovation and growth in the clinical communication and collaboration market.

North America dominates the global Clinical Communication and Collaboration market.

The Clinical Communication and Collaboration market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2023, North America accounted for the largest share of the Clinical Communication and Collaboration market. This region’s dominance is due to highly developed healthcare infrastructure characterized by advanced technology adoption, robust regulatory frameworks, and a strong emphasis on patient-centric care delivery. Moreover, the presence of key market players such as Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US) among others are a key factor contributing to the growth of the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=118830286

Key Market Players of Clinical Communication & Collaboration Industry:

Prominent players in the Clinical Communication and Collaboration market include Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US), Baxter International (Hillrom) (US), symplr (US), NEC Corporation (Japan), Spok Inc. (US), Vocera Communications (Stryker) (US), Ascom Holding AG (Switzerland), Everbridge (US), Hidden Brains InfoTech. (India), Imprivata, Inc. (US), CommuniCare Technology, Inc. d/b/a Pulsara (US), Mobile Heartbeat (C-HCA, Inc.) (US), OnPage. (US), HARRIS ONPOINT (US), Jive Software, LLC (US), TigerConnect (US), JCT Healthcare Pty Ltd. (Australia), Amplion (US), AndorHealth (US), PerfectServe, Inc. (US), QliqSOFT, Inc. (US), and Connexall, GlobeStar Systems Inc. (Canada).

Cisco Systems, Inc. (US)

Cisco has continued to enhance its overall clinical communication and collaboration solutions with a significant focus on Al, which it calls cognitive collaboration. One of Cisco’s biggest moves this past year was its launch of a unified client that brings Cisco Webex (cloud collaboration) and its on- premises Cisco Unified Communications Manager capabilities together as one common user experience. Cisco’s CC&C portfolio is led by its Cisco Webex Collaboration cloud, which combines Webex video meetings, calling, team collaboration, and collaboration devices. Cisco also offers Webex Contact Center, which is a cloud contact center service integrated with the Webex UCC suite

Oracle (US)

Oracle is one of the leading provider of HCIT solutions and support & maintenance services. The company Cerner’s device connectivity solutions allow interoperability between medical devices, healthcare applications and the EHR, regardless of vendor, enabling clinicians to streamline their workflows and focus more on their patients. Oracle’s geographical operations span across North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Along with understanding customer needs, the company has maintained robust relationships with existing suppliers, thus contributing to its strong supply chain in the market. Thus, leveraging its extensive expertise in database management, cloud computing, and enterprise applications, Oracle has developed robust communication and collaboration solutions.

Avaya LLC (US)

Avaya LLC (US) stands as one of the prominent players in the clinical communication and collaboration market, offering innovative solutions tailored to the specific needs of healthcare organizations. With a strong track record in providing communication and collaboration technologies across various industries, Avaya has positioned itself as a trusted partner for healthcare providers seeking to enhance care delivery efficiency and patient outcomes. The company distinguishes itself through its customer-centric approach and commitment to providing tailored solutions that address the unique challenges and priorities of healthcare organizations. By collaborating closely with 5000+ healthcare organizations the company has built long-lasting relationships with its clients and has established itself as a leader in the clinical communication and collaboration market.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=118830286

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/clinical-communication-collaboration-market-118830286.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Clinical Communication & Collaboration Market Top Companies Analysis, Industry Size, Share, Demand, Growth, In-Depth Insight, Business Opportunities And Forecast 2029

Surgical Suction Instruments Market to Hit USD 503 Million by 2029

“Cardinal Health, Inc. is a global healthcare services and products company headquartered in Dublin, Ohio. They are a major player in the US healthcare system. They are a global manufacturer and distributor of a wide range of medical and laboratory products, including surgical instruments, gloves, syringes, catheters, and diagnostic test kits”

Key players in the surgical suction instruments market include Olympus (Japan), Cardinal Health, Inc. (US), Stryker Corporation (US), Medtronic (Ireland), B. Braun Melsungen AG (Germany), CONMED Corporation (US), BD (US)

The global surgical suction instruments market, valued at US$355 million in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching US$375 million in 2024 and an impressive US$503 million by 2029. Surgical suction instruments is rapidly transforming the industry, offering significant advantages for manufacturers. The global rise in chronic disease prevalence, particularly among the aging population, is a major driver for the demand for surgical suction instruments. Advancements in surgical suction technology are creating new possibilities, offering greater functionality and improving surgical procedures. As developing countries experience economic growth and rising disposable income, healthcare infrastructure improves. This leads to a greater demand for surgical procedures and related equipment like suction instruments.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=129636225

Browse in-depth TOC on “Surgical Suction Instruments Market“

390 – Tables

300 – Figures

400 – Pages

Surge in Surgical Procedures Fuels Demand for Suction Instruments

The escalating number of surgeries globally serves as a prime catalyst for the surgical suction instruments market. With surgeries on the rise, the demand for these vital tools intensifies, ensuring optimal surgical conditions, minimizing complications, and enhancing patient outcomes. This upward trajectory is anticipated to persist, driving sustained market growth.

Balancing Innovation with Risks of Surgical Suction Instruments

While surgical suction instruments play a crucial role in medical procedures, complications such as unintended tissue injury and infection pose significant challenges. Improper usage or excessive suction power can lead to adverse outcomes, necessitating meticulous technique and careful suction level selection, especially in laparoscopic procedures. Addressing these risks is vital to ensuring market stability and growth.

Sustainable Solutions: The Rise of Biodegradable Materials in Surgical Instruments

The growing demand for eco-friendly practices in healthcare settings presents a promising opportunity for the adoption of biodegradable materials in surgical instruments. Unlike traditional plastics, biodegradable alternatives offer a sustainable option, decomposing naturally after disposal and reducing environmental impact. This trend aligns with the industry’s focus on sustainability, paving the way for market expansion and innovation.

Navigating Complexities in Cleaning and Disinfection of Advanced Instruments

The cleaning and disinfection of advanced surgical suction instruments pose a formidable challenge due to intricate designs and delicate components. Thorough cleaning is essential to maintain functionality and prevent damage, yet harsh chemicals and aggressive scrubbing techniques can compromise instrument integrity. Addressing these complexities is crucial for sustaining market growth amidst evolving technological advancements.

Competitive Landscape and Market Pressures in the Surgical Instruments Industry

The surgical suction instruments market witnesses increasing competition as new entrants join and established players vie for market share. This competition drives down prices, exerting pressure on medtech businesses to balance profitability with competitiveness. Consolidation within the industry and shifts in healthcare policies further impact market dynamics, requiring players to adapt pricing strategies to navigate regulatory changes and reimbursement rates.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=129636225

Yankauer Suction Tubes Forecasted to Lead Surgical Suction Instruments Market Growth

Within the surgical suction instruments industry, the yankauer suction tube segment is anticipated to exhibit the highest CAGR from 2024 to 2029. This segment encompasses various types, including retractors, yankauer suction tubes, poole suction tubes, frazier suction tips, and others. Yankauer tubes, distinguished by their cost-effectiveness and durability, particularly stand out among specialized disposable suction tips. Crafted from premium medical-grade materials like stainless steel, yankauer tubes offer reusability after proper sterilization, thus propelling segment growth.

Surge in General Surgery Applications to Drive Market Expansion

The general surgery segment is poised to witness the highest CAGR in the surgical suction instruments industry from 2024 to 2029. Suction instruments play a pivotal role in removing blood, fluids, and debris from surgical sites, enhancing visualization and facilitating precise dissection while minimizing tissue damage. Moreover, during procedures involving electrocautery, suction aids in clearing smoke, improving visibility, and mitigating the risk of smoke inhalation for both surgical teams and patients, thereby fostering segment growth.

Hospitals and Clinics Segment to Spearhead Market Advancement

The hospital and clinics segment is forecasted to demonstrate the highest CAGR in the surgical suction instruments industry from 2024 to 2029. This surge in demand is propelled by the critical role these institutions play in meeting escalating surgical needs, driving the necessity for essential tools like surgical suction instruments. Vital for enhancing surgical outcomes, patient satisfaction, and infection control, the demand for these instruments is expected to persist, underpinning segment growth in the foreseeable future.

North America Emerges as Key Driver of Surgical Suction Instruments Market

North America emerges as a dominant force in the global surgical suction instruments industry, boasting the largest CAGR among regions during the forecast period. This growth is attributed to various factors, including governmental initiatives promoting health awareness and subsidizing treatments, thereby stimulating market expansion. The region experiences a significant uptick in demand for surgical suction instruments, driven by evolving patient needs and dynamic shifts in the healthcare landscape.

CARDINAL HEALTH, INC. (US)

Cardinal Health, Inc. is a global healthcare services and products company headquartered in Dublin, Ohio. They are a major player in the US healthcare system. They are a global manufacturer and distributor of a wide range of medical and laboratory products, including surgical instruments, gloves, syringes, catheters, and diagnostic test kits. Cardinal Health serves nearly 90% of US hospitals, over 60,000 US pharmacies, and more than 10,000 specialty physician offices and clinics. They also have a global presence in several other countries. Cardinal Health emphasizes improving patient outcomes and supporting medication adherence.

STRYKER CORPORATION (US)

Stryker Corporation is a leading global medical technology company headquartered in Kalamazoo, Michigan. They focus on delivering innovative medical devices, implants, and equipment that improve patient outcomes and healthcare provider efficiency.

pen_spark. Stryker is a prominent medical device company with a focus on orthopaedics, neurotechnology, biosurgery, and medical, surgical, and neurovascular products. Stryker doesn’t appear to be a major player in the general surgical suction instrument market. Their focus seems to be on fluid management systems and related products that indirectly involve suction, primarily within their core specialties.

MEDTRONIC (IRELAND)

Medtronic plc is a leading global healthcare company headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota. They specialize in the development, manufacture, and distribution of medical devices and therapies for a wide range of medical conditions. The Medtronic medical surgical segment offers a broad range of surgical tools and equipment for general surgery, neurosurgery, spine surgery, and ear, nose, and throat (ENT) procedures. It’s possible that some surgical suction instruments fall under this category.

For more information, inquire now! Inquire Now

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Surgical Suction Instruments Market to Hit USD 503 Million by 2029

Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

DelveInsight’s, “Alpha 1 Antitrypsin Deficiency Pipeline Insight” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Alpha 1 Antitrypsin Deficiency pipeline landscape. It covers the Alpha 1 Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alpha 1 Antitrypsin Deficiency therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Alpha 1 Antitrypsin Deficiency pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Alpha 1 Antitrypsin Deficiency Pipeline Report to explore emerging therapies, key Alpha 1 Antitrypsin Deficiency Companies, and future Alpha 1 Antitrypsin Deficiency treatment landscapes @ Alpha 1 Antitrypsin Deficiency Pipeline Outlook Report

Key Takeaways from the Alpha 1 Antitrypsin Deficiency Pipeline Report

In February 2025:- Grifols Therapeutics Inc.:- The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).
In January 2025:- Takeda:- The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease.
In January 2025:- Korro Bio Inc.:- The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).
In January 2025:- Arrowhead Pharmaceuticals:– The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
In January 2025:- Kamada Ltd:- The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).
DelveInsight’s Alpha 1 Antitrypsin Deficiency pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Alpha 1 Antitrypsin Deficiency treatment.
The leading Alpha 1 Antitrypsin Deficiency Companies such as Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.
Promising Alpha-1 Antitrypsin Deficiency Pipeline Therapies such as Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, ADVM-043, and others.

Discover how the Alpha 1 Antitrypsin Deficiency treatment paradigm is evolving. Access DelveInsight’s in-depth Alpha 1 Antitrypsin Deficiency Pipeline Analysis for a closer look at promising breakthroughs @ Alpha 1 Antitrypsin Deficiency Clinical Trials and Studies

Alpha 1 Antitrypsin Deficiency Emerging Drugs Profile

ARO AAT: Arrowhead Pharmaceuticals

ARO AAT is a second generation, N-Acetylgalactosamine (GalNAc) based, subcutaneously administered RNA interference based therapeutic. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. In June 2019, the US FDA has granted Fast Track designation to ARO-AAT. ARO-AAT is in Phase III clinical studies for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD).

ALN-AAT02: Alnylam Pharmaceuticals

ALN AAT02 is a subcutaneously administered RNAi therapeutic that targets alpha-1 antitrypsin (AAT). ALN-AAT02 is based on the Alnylam’s enhanced stabilization chemistry plus (ESC+)-GalNAc-conjugate technology, which enables subsequent subcutaneous dosing with increased selectivity and a wide therapeutic index. The drug is currently in Phase I/II clinical development for the treatment of ZZ Type AAT Deficiency Liver Disease.

The Alpha 1 Antitrypsin Deficiency pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Alpha 1 Antitrypsin Deficiency with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha 1 Antitrypsin Deficiency Treatment.
Alpha 1 Antitrypsin Deficiency Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alpha 1 Antitrypsin Deficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha 1 Antitrypsin Deficiency market.

Get a detailed analysis of the latest innovations in the Alpha 1 Antitrypsin Deficiency pipeline. Explore DelveInsight’s expert-driven report today! @ Alpha 1 Antitrypsin Deficiency Unmet Needs

Alpha 1 Antitrypsin Deficiency Companies

Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.

Alpha 1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Alpha 1 Antitrypsin Deficiency Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Alpha 1 Antitrypsin Deficiency Therapies and key Alpha 1 Antitrypsin Deficiency Developments @ Alpha 1 Antitrypsin Deficiency Market Drivers and Barriers, and Future Perspectives

Scope of the Alpha 1 Antitrypsin Deficiency Pipeline Report

Coverage- Global
Alpha 1 Antitrypsin Deficiency Companies- Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.
Alpha-1 Antitrypsin Deficiency Pipeline Therapies– Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101/rhAAT-Fc, ADVM-043, and others.
Alpha 1 Antitrypsin Deficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Alpha 1 Antitrypsin Deficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Alpha 1 Antitrypsin Deficiency drug development? Find out in DelveInsight’s exclusive Alpha 1 Antitrypsin Deficiency Pipeline Report—access it now! @ Alpha 1 Antitrypsin Deficiency Emerging Drugs and Major Companies

Table of Content

Introduction
Alpha-1 Antitrypsin Deficiency Executive Summary
Alpha-1 Antitrypsin Deficiency: Overview
Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics
Alpha-1 Antitrypsin Deficiency Pipeline Therapeutic Assessment
Alpha-1 Antitrypsin Deficiency– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ARO AAT: Arrowhead Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
ALN-AAT02: Alnylam Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Alpha-1 Antitrypsin Deficiency Key Companies
Alpha-1 Antitrypsin Deficiency Key Products
Alpha-1 Antitrypsin Deficiency- Unmet Needs
Alpha-1 Antitrypsin Deficiency- Market Drivers and Barriers
Alpha-1 Antitrypsin Deficiency- Future Perspectives and Conclusion
Alpha-1 Antitrypsin Deficiency Analyst Views
Alpha-1 Antitrypsin Deficiency Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-lasers-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

Glioblastoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

DelveInsight’s, “Glioblastoma Pipeline Insight” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Glioblastoma pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Glioblastoma Pipeline Report to explore emerging therapies, key Glioblastoma Companies, and future Glioblastoma treatment landscapes @ Glioblastoma Pipeline Outlook Report

Key Takeaways from the Glioblastoma Pipeline Report

In February 2025:- NovoCure GmbH:- This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
In January 2025:- NuvOx LLC:- This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
In January 2025:- Philogen S.p.A:- The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
In January 2025:- Genenta Science:- This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid specific interferon-alpha2 expression, which will be administered to up to 27 patients affected by GBM who have an unmethylated MGMT promoter. Part A will evaluate the safety and tolerability of 5 escalating doses of Temferon and 3 different conditioning regimens in up to 27 patients, following first line treatment.
DelveInsight’s Glioblastoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioblastoma treatment.
The leading Glioblastoma Companies such as Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.
Promising Glioblastoma Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.

Discover how the Glioblastoma treatment paradigm is evolving. Access DelveInsight’s in-depth Glioblastoma Pipeline Analysis for a closer look at promising breakthroughs @ Glioblastoma Clinical Trials and Studies

Glioblastoma Emerging Drugs Profile

Enzastaurin: Denovo BioPharma

DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world’s first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

Asunercept: Apogenix

CAN008 (asunercept) is a CD95-Fc fusion protein that binds to the CD95 ligand and blocks the interaction between the ligand and the endogenous CD95 receptor. CAN008 has a unique dual mechanism of action, inhibiting both the invasive growth and migration of tumor cells, as well as T-cell apoptosis, which enhances immune recognition of the cancer. Earlier asunercept glioblastoma multiforme (GBM) clinical trial data showed favorable safety and tolerability, prolonged survival and improved quality-of-life. Asunercept has been granted US FDA Orphan Drug Designation and Orphan Medicinal Product Designation by the European Medicines Agency (EMA) for GBM. It has also been accepted into the EMA’s PRIME (Priority Medicines) program, which provides support to medicines that could address unmet medical needs. In China, CAN008 has been classified as a Class 1 New Drug by the National Medical Products Administration. CANbridge holds the rights to develop and commercialize CAN008 for any indication in Greater China and is currently conducting a CAN008 Phase II trial in GBM in China.

Berubicin: CNS Pharmaceuticals

Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Glioblastoma.

Azeliragon: Cantex

Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer’s disease by vTv Therapeutics from which Cantex licensed worldwide rights to azeliragon. Currently, the drug is in Phase II stage of its clinical trial for the treatment of glioblastoma, brain metastasis, pancreatic cancer, breast cancer.

VXM01: VAXIMM

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Glioblastoma.

MB-101: Mustang Bio

MB-101 is a CAR-T cell therapy developed by Mustang Bio that targets IL13Rα2, a protein expressed on the surface of certain glioma cells. The therapy involves the infusion of CAR-T cells that are engineered to recognize and bind to IL13Rα2, leading to the activation and proliferation of these cells. This results in the killing of glioma cells and the potential for long-term remission. MB-101 has shown promising results in clinical trials, including achieving complete responses in two patients with high-grade glioma, and has been well-tolerated with manageable side effects. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioblastoma.

The Glioblastoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

Get a detailed analysis of the latest innovations in the Glioblastoma pipeline. Explore DelveInsight’s expert-driven report today! @ Glioblastoma Unmet Needs

Glioblastoma Companies

Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Glioblastoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Glioblastoma Therapies and key Glioblastoma Developments @ Glioblastoma Market Drivers and Barriers, and Future Perspectives

Scope of the Glioblastoma Pipeline Report

Coverage- Global
Glioblastoma Companies- Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.
Glioblastoma Therapies– Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.
Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Glioblastoma drug development? Find out in DelveInsight’s exclusive Glioblastoma Pipeline Report—access it now! @ Glioblastoma Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Glioblastoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Glioblastoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Enzastaurin: Denovo BioPharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Asunercept: Apogenix
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MB-101: Mustang Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Glioblastoma Key Companies
Glioblastoma Key Products
Glioblastoma- Unmet Needs
Glioblastoma- Market Drivers and Barriers
Glioblastoma- Future Perspectives and Conclusion
Glioblastoma Analyst Views
Glioblastoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

Malaysia Elevator & Escalator Market Growth Forecast Report 2024-2030: 3.54 Thousand Units of New Installation Predicted – Arizton

“Malaysia elevator and escalator market research report by Arizton”

According to Arizton’s latest research report, the Malaysia elevators & escalators market is growing at a CAGR of 4.72% during 2024-2030.

Looking for More Information? Click: https://www.arizton.com/market-reports/malaysia-elevator-and-escalator-market

Report Scope:    

Market Size by New Installations (2030): 3.54 Thousand Units

Market Size by New Installations (2024): 2.69 Thousand Units

CAGR – New Installations (2024-2030): 4.72%

Market Size by Installed Base (2030): 106.57 Thousand Units

Market Size by Modernization (2030): $130.65 Million

Historic Year: 2021-2023

Base Year: 2024

Forecast Year: 2025-2030

Malaysia Elevators and Escalators Market Shows Strong Growth Trajectory

The elevators and escalators market in Malaysia is on a strong growth path, fueled by several key factors contributing to its expansion. Rapid urbanization and infrastructure development are driving the demand for vertical transportation solutions, especially in high-rise residential and commercial buildings. The growing real estate sector, supported by a favorable regulatory environment and government initiatives, is further boosting the need for advanced elevators and escalators.

Tourism also plays a significant role, with the government’s efforts to promote the sector driving foreign investment in the hospitality industry. Additionally, the increasing need for modernization and maintenance of aging buildings, particularly in urban areas like Kuala Lumpur, is contributing to the demand for elevator upgrades.

Technological advancements, such as the integration of artificial intelligence (AI) in vertical transportation systems, are shaping the future of the market. A recent example is the launch of the AI-driven Nibav Series 4 smart home lift in Malaysia. Furthermore, real estate developers remain optimistic about the property market, supported by anticipated economic growth, stable interest rates, and legislative changes aimed at improving affordability and housing supply. The overall outlook for the Malaysia elevators and escalators market remains positive, with strong growth expected in the coming years.

Recent Developments in the Malaysia Elevator and Escalator Market

In August 2024, Otis unveiled its Gen3™ connected elevator platform at its ‘Platform for Possibility’ launch event in Kuala Lumpur.
In 2024, Mitsubishi Electric Building Solutions Corporation announced its new elevator type, ‘NEXIEZ-Fit’, which is an elevator that combines superior cost performance with carefully selected specifications.
In September 2024, Kone announced its New 2025-2030 Strategy “Rise”.

AI Integration in Elevators and Escalators: Unlocking Future Market Opportunities in Malaysia

The integration of artificial intelligence (AI) in elevators and escalators is transforming the industry, particularly in Malaysia, as part of the broader trend toward modernizing urban infrastructure. AI-driven solutions are enhancing safety, efficiency, and user experience by monitoring real-time data from sensors, predicting potential malfunctions, and preventing downtime. Leading companies like KONE, Otis, and Mitsubishi Elevator are already embracing AI technology. For example, Otis launched its Gen3 digitally connected elevator in Southeast Asia, incorporating advanced digitization and machine learning to ensure seamless updates and adaptability. Similarly, KONE’s DX Class lifts utilize AI to store and analyze data, improving lift maintenance and reducing malfunctions. These innovations are expected to create significant growth opportunities in the Malaysia elevators and escalators market, boosting both operational reliability and user satisfaction.

Rising Demand for Hydraulic and Pneumatic Elevators in Malaysia’s Growing Construction Market

As Malaysia experiences significant growth in both residential and non-residential construction, hydraulic and pneumatic elevators are expected to see higher demand in 2025. Hydraulic elevators, although energy-intensive, remain essential in buildings with lower heights, while pneumatic elevators are gaining popularity in residential projects due to their space-saving and mobility benefits. A prime example of Malaysia’s booming construction sector is Sunsuria Bhd’s proposed Nadi @ TAR project, a high-rise mixed-use development with office and retail spaces, set to be completed by the end of 2025. Additionally, innovations like TK Elevator’s MAX platform, which integrates cloud-based data for building operations, are enhancing vertical mobility systems, offering property owners and managers streamlined operations and improved accessibility. This growing focus on advanced construction projects and building management systems is driving the demand for diverse elevator solutions in Malaysia’s evolving market.

Book the Free Sample Now: https://www.arizton.com/market-reports/malaysia-elevator-and-escalator-market

Key Vendors

Otis
KONE
TK Elevator
Schindler
Mitsubishi Electric
Hitachi
Hyundai Elevator
Fujitec
Toshiba Elevator and Building Systems Corporation
Stannah Lifts Holdings Ltd
EITA Elevator
Stannah Lifts Holdings Ltd
Nippon Elevator
DOVER Elevators
CE Elevator
Delfar Elevator
Wiitrac Elevator
Dong Yang Elevator
Nibav Lifts

Elevator Market Segmentation

Machine Type

Hydraulic and Pneumatic
Machine Room Traction
Machine Room Less Traction
Others
Climbing
Elevators
Industrial Elevators

Carriage Type

Passenger
Freight

Capacity

2-15 Persons
16-24 Persons
25-33 Persons
34 Persons and Above

End-User

Commercial
Residential
Industrial
Others
Public Transit
Institutional
Infrastructural

Escalator Market Segmentation

Product Type

Parallel
Multi Parallel
Walkway
Crisscross

End-User

Public Transit
Commercial
Others
Institutional Sector
Infrastructure
Industrial

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the Malaysia elevator and escalator market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/malaysia-elevator-and-escalator-market

What Key Findings Will Our Research Analysis Reveal?  

How big is the Malaysia elevator and escalator market?

What will be the growth rate of the Malaysia elevator and escalator market?

What is the number of installed bases in the Malaysia elevator and escalator market in 2024?

What are the key opportunities in the Malaysia elevator and escalator industry?

What are the key Malaysia elevator and escalator market players?

Other Related Reports that Might be of Your Business Requirement  

Thailand Elevator and Escalator Market – Size & Growth Forecast 2025-2030

https://www.arizton.com/market-reports/thailand-elevators-and-escalators-market

Asia Pacific Elevator and Escalator – Market Size & Growth Forecast 2024-2029

https://www.arizton.com/market-reports/asia-pacific-elevator-and-escalator-market

Why Arizton?                                             

100% Customer Satisfaction                                             

24×7 availability – we are always there when you need us                                             

200+ Fortune 500 Companies trust Arizton’s report                                             

80% of our reports are exclusive and first in the industry                                             

100% more data and analysis                                             

1500+ reports published till date                           

Post-Purchase Benefit                                         

1hr of free analyst discussion                                         
10% off on customization

About Us:                                                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/malaysia-elevator-and-escalator-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Malaysia Elevator & Escalator Market Growth Forecast Report 2024-2030: 3.54 Thousand Units of New Installation Predicted – Arizton

Methanol Market Top Companies Analysis, Industry Size, Share, Demand, Growth, In-Depth Insight, Business Opportunities And Forecast 2028

“Browse 656 market data Tables and 60 Figures spread through 487 Pages and in-depth TOC on “Methanol Market””

The methanol industry is expanding, driven by rising demand in chemicals, energy, and clean fuel applications. Key players like Methanex, SABIC, Celanese, and OCI N.V. are investing in capacity expansion and sustainable production. Asia-Pacific dominates the market, with innovations in MTO technology and bio-methanol shaping future growth.

Methanol (CH₃OH) is a key chemical used in producing formaldehyde, acetic acid, and plastics. It is also gaining demand as a cleaner fuel in automotive and marine industries. With growing applications in chemicals and energy, the global methanol market is expanding, especially in Asia-Pacific, driven by MTO technology and bio-methanol advancements. The methanol market is projected to grow from USD 30.9 billion in 2023 to USD 38.0 billion by 2028, at a CAGR of 4.2% from 2023 to 2028. The growth in the market is driven by the rising demand in various end-use industries such as automotive, pharmaceutical, construction, among others. The market research report provides access to critical information such as methanol market growth drivers, market growth restraints, current market trends, the market’s economic and financial structure, and other key market details. Methanol is used in various industries, such as Construction, Automotive, Electronics, Appliances, Paints & Coatings, Insulation, Pharmaceuticals, Packaging (PET bottles), Solvents, among others.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=425

By feedstock, the coal segment accounted for the fastest-growing of the methanol market during 2023 to 2028

The coal segment, by feedstock, market accounts for the fastest growth. Many countries are shifting towards coal feedstock due to high prices and limited reserves of natural gas in certain areas. For the manufacturing methanol from coal, it is mixed with air separator O2 and then put through coal gasification to create crude syngas. Methanol manufacturing using coal as a feedstock is a carbon-intensive process that can produce a lot of greenhouse gas emissions. Utilizing cleaner and more environmentally friendly feedstocks for the manufacturing of methanol has received increased attention in recent years in an effort to reduce environmental impact.

By derivative, the MTO/MTP segment accounted for the fastest-growing share of the methanol market during 2023 to 2028

The MTO/MTP segment, by derivative, market accounts for the fastest growth. The growth is due to the rise in MTO/CTO plants in China to produce olefins through methanol, as the demand for olefins is growing in the petrochemical industry. The chemical industry has paid close attention to the MTO and MTP processes because they offer an alternate method of producing olefins from non-petroleum feedstocks like methanol. The growing demand for methanol is highly attributed to its increasing demand in the automotive and construction end-use industries.

By sub derivative, the olefins segment accounted for the fastest-growing share of the methanol market during 2023 to 2028

The olefins segment, by sub derivative, market accounts for the fastest growth. The growth is due to an increase in production of methanol and high feedstock availability. Methanol is alternative source to produce light olefins which is currently high in demand in various applications. Olefins are essential raw materials for the manufacturing of various plastics, synthetic fibres, rubber, and other petrochemical goods, with ethylene and propylene playing a particularly important role. Olefin production from methanol offers an alternative feedstock method, hence diversifying the sources of these important chemical building blocks.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=425

By end-use industry, the solvent segment accounted for the fastest-growing share of the methanol market during 2023 to 2028

The solvent segment, by end-use industry, market accounts for the fastest growth. This growth is due to the huge demand from the various end-use industries. Methanol is used as a laboratory solvent, which is useful for HPLC, UV/VIS spectroscopy, and LCMS due to its low UV cutoff. Methanol is commonly used as a solvent in industrial processes, such as those involving the production of chemicals, medications, and electronics. It is helpful for cleaning, degreasing, and extracting items since it can dissolve a wide variety of organic compounds, including oils, resins, polymers, dyes, and dye molecules. The solvent qualities of methanol make it useful in formulas for paint and coatings, printing inks, and cleaning agents.

Asia Pacific is the largest region in the Methanol market.

Asia Pacific accounted for the largest share of the methanol market in 2022. Factors such as the rapidly increasing consumption of methanol in the various end-use industries in countries such as China, Japan, India, South Korea and Australia have led to an increased demand for Methanol in the Asia Pacific region.In the Asia Pacific region, methanol use as an alternative fuel has drawn attention. There is a growing need for methanol as a fuel, particularly in transportation and power generation, and it can be used solely as fuel or combined with petrol in some situations.

Methanol Companies

Companies such as Methanex Corporation (Canada), HELM Proman Methanol AG, SABIC (Saudi Arabia), Yankuang Energy Group Company Limited (China), and Zagros Petrochemical Company (ZPC) (Iran) fall under the winners’ category. These are leading players in the methanol market, globally. These players have adopted the strategies of acquisition, agreement, investment, joint venture, merger, product launch, expansion, divestment, and partnership to fulfil the rising demand for methanol on the regional as well as global levels.

Methanex Corporation

Methanex Corporation is one of the leading manufacturers of methanol. The company has a geographic presence in North America, Europe, Asia Pacific, South America, and the Middle East. Methanol manufactured by company is used in building materials, foams, resins, and plastics. In April 2023, Methanex Corporation and Suez Methanol Derivatives (SMD) signed an agreement for a new methanol pipeline construction.

Zagros Petrochemical Company

Zagros Petrochemical Company is one of the largest methanol companies is Iran. The company manufactures methanol that is used in manufacturing formaldehyde, acetic acid, and many other products. In March 2023, Zagros Petrochemical Company signed an agreement with Dalian Petrochemical Company to construct a methanol-to-synthetic ethanol conversion plant.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=425

SABIC

SABIC engages in the manufacture, marketing and distribution of petrochemicals, polymers and plastics, and agricultural nutrients. The company is one of the key players in the methanol market and has a geographic presence in more than 100 countries. In September 2021, SABIC formed a joint venture with ExxonMobil to strengthen its petrochemical manufacturing presence in North America.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Methanol Market Top Companies Analysis, Industry Size, Share, Demand, Growth, In-Depth Insight, Business Opportunities And Forecast 2028

NFC Market worth $30.55 Billion by 2029, at a CAGR of 7.1%

“NFC Market”

The global NFC Market in terms of revenue is estimated to be worth $21.69 billion in 2024 and is poised to reach $30.55 billion by 2029, growing at a CAGR of 7.1% during the forecast period.

The report “NFC Market by Offering (NFC ICs, NFC Antennas, NFC Tags, NFC Readers), Operating Mode (Reader Emulation, Peer-to-Peer, Card Emulation), Use Cases (Payment and Transactions, Product Identification, Ticketing, Access Control) – Global Forecast to 2029” The global NFC industry will USD 30.55 billion by 2029 from USD 21.69 billion by 2024, at a CAGR of 7.1% during the forecast period. Rapid industrialization and urbanization prevail largely in the emerging economies of China and India, particularly through the development of smart cities. Gradual concentration in industrial development has increased demand for the infrastructure required in cities. This would eventually lead to the development of educational & healthcare institutions, public administration offices, shopping malls, stores, and warehouses. This, in turn, will boost the demand for advanced NFC solutions and smartcard, particularly in technologically advancing countries such as India, China, and Brazil.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=520

Browse 221 market data Tables and 74 Figures spread through 217 Pages and in-depth TOC on “NFC Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/near-field-communication-nfc-market-520.html

The market for NFC Hardware segment is expected to gain a significant market share during the forecast period.

NFC hardware products are internal NFC-enabled accessories that are built into the device to facilitate NFC communication. These include NFC IC/Chips designed for smartphones to make contactless payments, access control, and secure paring with other NFC devices for data sharing. NFC tags are similar to RFID tags that are used to store small but essential data used as readers and access control devices. NFC tags are similar to RFID tags and are used to store essential data in a compact format. This data can be read and accessed by NFC readers or NFC-enabled smartphones. NFC tags are commonly utilized for proximity and vicinity identification. Some of their applications include transit systems, ticketing, access control, and offline authentication through digital signatures.

The transportation segment is to grow at an impressive CAGR during the forecast period.

In the transportation industry, the NFC-enabled phone transactions can be used with existing contactless infrastructure, which requires no additional investment. NFC enables two-way communications such as redeeming a ticket and sensing a receipt. NFC forum tags placed behind posters and other printed media (smart posters) allow travelers to touch and read schedules, get special offers, and learn about destination highlights. The major applications of NFC in the transportation industry are ticketing and access control. NFC-enabled smartphones and travel cards allow passengers to simply use their personal devices/cards on designated readers to validate their tickets or access rail, metro, and airport stations. NFC adds several benefits in all stages of ticketing such as convenience, security, and flexibility. Proof of ticket registration, special travel discount coupons and entitlements can be stored on the phone or travel cards.

North America is expected to grow at significant CAGR during the forecast period.

North America is one of the leading markets for NFC in terms of R&D, network design/deployment, and the presence of key industry players such as Broadcom (US), Qualcomm Technologies, Inc. (US), Texas Instruments Incorporated (US), and Flomio, Inc. (US). In North America, the US is considered to have the most engaged mobile user base, and this is expected to grow with the addition of new subscribers. Full-fledged NFC implementation in North America is expected to boost retail services. In the current scenario, the market for such services is growing continuously. The US is a leading adopter of advanced technologies committed to implementing automation solutions across various sectors. It ranks among the top three countries for spending on smart city initiatives and is also one of the top five nations in industrial automation investments. Additionally, smartphone penetration rate is high in the country, which has facilitated the widespread adoption of wired and wireless technologies.

The key companies in the NFC industry include NXP Semiconductors (Netherlands), Broadcom (US), Qualcomm Technologies, Inc. (US), Texas Instruments Incorporated (US), STMicroelectronics (Switzerland), Renesas Electronics Corporation (Japan), ams-OSRAM AG (Austria), Thales (France), and Infineon Technologies AG (Germany).

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Delray Beach
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/near-field-communication-nfc-market-520.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NFC Market worth $30.55 Billion by 2029, at a CAGR of 7.1%

Metastatic Colorectal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Colorectal Cancer pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Colorectal Cancer Pipeline Report to explore emerging therapies, key Metastatic Colorectal Cancer Companies, and future Metastatic Colorectal Cancer treatment landscapes @ Metastatic Colorectal Cancer Pipeline Outlook Report

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

In February 2025:- Buzzard Pharmaceuticals:- This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investoigators are testing a new type of immunotherapy aclled isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this otherwise effective treatment to work on this treatment resistant type of tumor.
In February 2025:- AbbVie:- Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC).
In January 2025:- Cardiff Oncology:- The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.
In January 2025:- Menarini Group:- This Phase Ib/II study will investigate the anti-tumour activity and safety of daily oral doses MEN1611 in combination with cetuximab in female and male patients affected by PIK3CA mutated, N-K-RAS wild-type and BRAF wild-type metastatic colorectal cancer.
In January 2025:- Amgen:- The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Metastatic Colorectal Cancer treatment.
The leading Metastatic Colorectal Cancer Companies such as Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech and others.
Promising Metastatic Colorectal Cancer Therapies such as Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.

Discover how the Metastatic Colorectal Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Colorectal Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Colorectal Cancer Clinical Trials and Studies

Metastatic Colorectal Cancer Emerging Drugs Profile

Lumakras (sotorasib): Amgen

Lumakras (sotorasib) is a highly selective inhibitor of KRAS G12C that potentially suppresses the rapid proliferation of cancer cells. Sotorasib forms an irreversible, covalent bond with the cysteine residue of KRAS G12C, holding the protein in its inactive form that blocks the oncogenic signaling. This results in apoptosis only in KRAS G12C tumor cell. It is being investigated as a treatment for a variety of solid tumors, including NSCLC, colorectal cancer and other solid tumor cancers. Currently, the drug is in the Phase III stage of its development for the treatment of Metastatic Colorectal Cancer.

Axitinib: Pfizer

Axitinib is an oral therapy that is designed to inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3; these receptors can influence tumor growth, vascular angiogenesis and progression of cancer. In the U.S., INLYTA is approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. Currently, the drug is in the Phase II stage of its development for the treatment of Metastatic Colorectal Cancer.

NX 1607: Nurix Therapeutics Inc

NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types. NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models. Nurix is evaluating NX-1607 in an ongoing, Phase I dose escalation and expansion trial in adults with a variety of oncology indications at multiple clinical sites. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.

TP-1454: Sumitomo Dainippon Pharma Oncology

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator that is currently being evaluated in a Phase I/I b study in patients with advanced metastatic or progressive solid tumors. TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.

The Metastatic Colorectal Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.
Metastatic Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.

Get a detailed analysis of the latest innovations in the Metastatic Colorectal Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Colorectal Cancer Unmet Needs

Metastatic Colorectal Cancer Companies

Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech and others.

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Colorectal Cancer Therapies and key Metastatic Colorectal Cancer Developments @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Colorectal Cancer Pipeline Report

Coverage- Global
Metastatic Colorectal Cancer Companies- Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech and others.
Metastatic Colorectal Cancer Therapies- Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.
Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Metastatic Colorectal Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Colorectal Cancer Pipeline Report—access it now! @ Metastatic Colorectal Cancer Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Metastatic colorectal cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Metastatic colorectal cancer Collaboration Deals
Late Stage Products (Phase III)
Lumakras (sotorasib): Amgen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Axitinib: Pfizer
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NX 1607: Nurix Therapeutics Inc
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Metastatic colorectal cancer Key Companies
Metastatic colorectal cancer Key Products
Metastatic colorectal cancer- Unmet Needs
Metastatic colorectal cancer- Market Drivers and Barriers
Metastatic colorectal cancer- Future Perspectives and Conclusion
Metastatic Colorectal Cancer Analyst Views
Metastatic Colorectal Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight

Insulation Coatings Market 2025 Top Business Strategy, Growth Factors, Healthy CAGR with Segments, Top Key Players & Forecast – 2028

“Browse 381 market data Tables and 50 Figures spread through 313 Pages and in-depth TOC on “Insulation Coatings Market””

The Insulation Coatings Market is driven by rising energy efficiency demands, strict environmental regulations, and industrial growth. Advancements in coating technology and increasing adoption in construction, automotive, and oil & gas sectors fuel market expansion. Asia-Pacific leads in demand, while North America and Europe see steady growth in sustainable solutions.

Insulation coatings are protective layers that reduce heat transfer, enhance energy efficiency, and prevent corrosion in industries like construction, oil & gas, and automotive. Rising demand is driven by energy efficiency regulations, sustainability goals, and industrial growth, especially in Asia-Pacific, North America, and Europe. The insulation coatings market is estimated to be USD 9.7 billion in 2022 and is projected to reach USD 14.4 billion by 2028, at a CAGR of 5.9% between 2023 and 2028. Protection of equipment, pipelines, and other components from harsh environments to make them energy efficient are the major drivers of the global insulation market during the forecast period. This report provides a comprehensive analysis of the industry including insulation coatings market size, trends, drivers and constraints, competitive aspects, and prospects for future growth.

Acrylic-based insulation coating type is estimated to be the largest type of insulation coatings material

Acrylic-based insulation coatings are waterborne coatings and account for the largest share in the overall Insulation coatings market. They serve as a superior alternative to conventional insulation materials, valued for their low-maintenance qualities and effectiveness in preventing corrosion under insulation (CUI). These coatings are easily applicable using user-friendly spray equipment and are well-suited for temperature ranges up to 150°C (302°F), with certain formulations extending their suitability to temperatures of up to 177°C (350.6°F).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=26484290

Industrial sector: the fastest-growing end-use industry for insulation coatings

Categorized by end-use industries, the insulation coatings market comprises five primary sectors: industrial, building and construction, aerospace, automotive, marine, and other applications. Among these, the industrial sector claims the largest share, with a primary application of thermal insulation. This usage facilitates reducing heat-related workplace injuries and promotes consistent temperatures for workers by minimizing heat dissipation from machinery. Additionally, these coatings assist in temperature control for chemicals and enhance workplace safety through electrical insulation, offering increased design versatility.

APAC is estimated to be the largest market for insulation coatings and is also projected to register the fastest CAGR of 6.9% during the forecast period. China holds for the maximum market share of 45.0% in 2022 in the Asia Pacific region. The primary drivers for the insulation coatings market in this region include expanding industrial operations, investing in insulation material utilization across various industries, and the impact of labor costs in these countries.

Insulation Coatings Companies

Insulation coating inhibits the transfer of sound, heat, or electricity from one surface area to another. These coatings aid in personnel protection, energy saving, and contribute to the improvement in the overall process efficiency. They are created using several materials such as acrylic, epoxy, polyurethane, mullite and yttria stabilized zirconia (YSZ).

Insulation coatings are utilized in a multiple applications like building and construction, to create a heat/electrical barrier in aircraft components, storage tanks, insulating pipelines, marine vessels, engine turbines, industrial equipment, and automobile components.

Most manufacturers in this market are based in Asia Pacific, Europe, and North America. AkzoNobel (Netherland), PPG (US), Sherwin-Williams Company (US), Kansai Paint Co., Ltd. (Japan), Jotun Group (Norway), Nippon Paint Holdings Co., Ltd. (Japan), Axalta Coating System (US), Hempel (Denmark), Seal for Life Industries (US), Carboline (US), and Sharpshell Engineering (South Africa), are among the leading players operating in the insulation coatings market. These players have adopted various growth strategies to strengthen their position in the market. This include product launches, expansions and acquisitions, and new product development activities further to expand their presence in the insulation coatings market.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=26484290

AkzoNobel

AkzoNobel is a major player in the paint and performance coatings industry, with two key segments: decorative paints and performance coatings. It’s known for various activities in the performance coating sector, including marine, metal, protective, powder, specialty coatings, and more. Resicoat, a significant brand, offers epoxy powder coatings for electrical insulation in applications like motors and electrical components. Operating globally with brands like International, Dulux, and Interpon, AkzoNobel has a strong presence in the Netherlands, US, Canada, Latin America, APAC, and Europe.

PPG

PPG produces and distributes paints, coatings, and specialized materials through two main divisions: performance coatings and industrial coatings. Their offerings include protective coatings, sealants, finishes, and more for various sectors like construction, consumer goods, and transportation. Operating globally, PPG has 243 facilities spanning the US, Americas, Europe, Middle East, Africa, and Asia Pacific. They provide coatings for construction machinery, packaging, aircraft, automotive, and more, providing contractors and consumers alike with a range of coatings. The company caters to painting and repair contractors, as well as individual consumers, providing coatings for decoration, maintenance, and both commercial and residential new construction.

Sherwin-Williams Company

The Sherwin-Williams Company develops, manufactures, and sells paints and coatings across three segments: America Group, Consumer Brands Group, and Performance Coating Group. Their products are available through a vast network of stores and facilities, including branded and private-label options. The Performance Coating Group supplies coatings for various industries. Sherwin-Williams operates globally, serving over 120 countries with diverse solutions for construction, industrial, packaging, and transportation sectors.

Kansai Paint Co., Ltd.

Kansai Paint Co., Ltd. produces and distributes diverse paint types, focusing on coatings, colour schemes, and biotech and electronics-related products. Operating across Japan, India, Asia, Africa, Europe, and other regions, they have a strong presence in Asia, especially India and Japan. The company manufactures insulation coating material under its product series named THERMOTECT.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=26484290

Jotun Group

The Jotun Group is involved in producing and selling a diverse range of paint and coating systems. Their operations span seven regional segments: Southeast Asia and Pacific, Northeast Asia, Middle East, India and Africa, West Europe and Scandinavia, East Europe and Central Asia, and Americas. Jotun’s business is divided into four segments: Decorative Paints, Marine Coatings, Protective Coatings, and Powder Coatings. These segments collectively aim to safeguard and protect properties using various paint and coating solutions. With 40 production facilities in 23 countries and a presence in over 100 countries through 67 companies, Jotun expands globally through subsidiaries, joint ventures, sales offices, and distribution channels.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Insulation Coatings Market 2025 Top Business Strategy, Growth Factors, Healthy CAGR with Segments, Top Key Players & Forecast – 2028

Gold Nears $3,000 Milestone: Undervalued Mining Stocks Set to Soar NGD, PNPN.V, ASM, PLG, YGT.V Amid Precious Metals Boom

As gold prices approach $3,000 per ounce, investors are eyeing undervalued mining stocks poised for major gains. Silver, copper, nickel, and platinum are also experiencing a bullish breakout, driven by geopolitical tensions, central bank gold reserves, and rising industrial demand.

Why Gold is Surging in 2025

Geopolitical Uncertainty & Inflation Hedge
- The U.S. imposed a 25% tariff on steel and aluminum imports, sparking concerns about trade disruptions and inflation. Gold remains the top safe-haven asset, attracting major institutional investment.
Central Bank Gold Buying Hits Record Highs
- China, Russia, and emerging markets have aggressively increased gold reserves as part of a global shift away from the U.S. dollar.
Physical Gold Demand Skyrockets
- The Commodity Exchange (COMEX) reported a record-breaking 52,577 gold contract deliveries, signaling a shift from paper trading to physical gold ownership.

Undervalued Mining Companies Benefiting from the Gold & Precious Metals Boom

New Gold Inc. (NYSE: NGD) (TSX: NGD)With gold prices surging, New Gold Inc. is one of the most undervalued gold stocks. Its Rainy River and New Afton mines in Canada are ramping up production, making NGD stock a key player in the gold bull market.
Gold Terra Resource Corp. (TSX.V: YGT) (OTCQB: YGTFF)Gold Terra is unlocking high-grade gold deposits in Canada’s Northwest Territories, positioning itself as an emerging leader among junior gold miners. With the Yellowknife City Gold Project, the company is attracting major investors looking for high-growth opportunities.

Silver, Nickel & Copper—The Next Big Investment Opportunities

Avino Silver & Gold Mines (AMEX: ASM) (TSX: ASM)Avino is a hidden gem among silver mining stocks, benefiting from both investment demand and industrial silver use. With increasing silver prices and strong production growth in Mexico, ASM stock is one to watch for silver bulls.
Power Nickel Inc. (TSX.V: PNPN) (OTCQB: PNPNF) has completed its strategic spin-out, forming two focused mining entities. Effective February 3, 2025, shareholders received one new Power Nickel share and 0.05 Chilean Metals shares per share held.
- Power Nickel will focus on its high-grade Nisk Project in Quebec.
- Chilean Metals will develop the Golden Ivan Property in British Columbia and its Chilean assets.
CEO Terry Lynch highlighted the value creation for shareholders, with Power Nickel advancing exploration and Chilean Metals preparing for drilling. While Power Nickel remains publicly traded, Chilean Metals will operate as a reporting issuer but won’t be exchange-listed.

As EV-driven nickel demand soars, Power Nickel’s high-grade assets position it as an undervalued stock in the battery metals sector.

Platinum & Palladium—A New Era for Industrial Metals

Platinum Group Metals (AMEX: PLG) (TSX: PTM)Platinum and palladium prices are surging as stricter emissions regulations drive demand for catalytic converters. Platinum Group Metals is leading exploration efforts, positioning itself as a major player in the global platinum group metals (PGM) supply chain.

Final Thoughts

As gold nears the historic $3,000 mark and other metals like silver, nickel, and platinum rally, these undervalued mining stocks could be the best investment opportunities in 2025. With strong market trends, increasing industrial demand, and record-breaking central bank purchases, now is the time to watch New Gold (NGD), Avino Silver & Gold Mines (ASM), Power Nickel (PNPN.V), Platinum Group Metals (PLG) and Gold Terra Resource Corp. (YGT.V) for their breakout potential.

Investors looking for high-growth mining stocks under $10 should keep a close eye on these companies as the next big winners in the precious metals bull market.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gold Nears $3,000 Milestone: Undervalued Mining Stocks Set to Soar NGD, PNPN.V, ASM, PLG, YGT.V Amid Precious Metals Boom